Advances in anti-tumor drugs with new mechanisms of action

doi:10.3760/cma.j.cn371439-20240318-00061

Abstract

Abstract:

Cytotoxic agents， molecular targeted agents and immune checkpoint inhibitors consist of the fundamental model of cancer systematic treatments. Anti-tumor drugs with new mechanisms of action， including kinase inhibitors， therapeutic antibodies， nucleic acid blocks， therapeutic vaccines， gene-edited immune cells， living microrobots and digital drugs， will change this existing model. Drugs targrting nerves， polysaccharides， lipids and microflora may gradually enter clinical applications.

Key words: Neoplasms, Antineoplastic agents, Therapy

Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.

References 55

[1]	Scott EC, Baines AC, Gong YT, et al. Trends in the approval of cancer therapies by the FDA in the twenty-first century[J]. Nat Rev Drug Discov, 2023, 22(8): 625-640. DOI: 10.1038/s41573-023-00723-4. pmid: 37344568
[2]	Micalizzi DS, Sequist LV, Haber DA. Deploying blood-based cancer screening[J]. Science, 2024, 383(6681): 368-370. DOI: 10.1126/science.adk1213. pmid: 38271495
[3]	Bedard PL, Hyman DM, Davids MS, et al. Small molecules, big impact: 20 years of targeted therapy in oncology[J]. Lancet, 2020, 395(10229): 1078-1088. DOI: 10.1016/S0140-6736(20)30164-1. pmid: 32222192
[4]	Morrison L, Loibl S, Turner NC. The CDK4/6 inhibitor revolu-tion—a game-changing era for breast cancer treatment[J]. Nat Rev Clin Oncol, 2024, 21(2): 89-105. DOI: 10.1038/s41571-023-00840-4. pmid: 38082107
[5]	Milletti G, Colicchia V, Cecconi F. Cyclers' kinases in cell division: from molecules to cancer therapy[J]. Cell Death Differ, 2023, 30(9): 2035-2052. DOI: 10.1038/s41418-023-01196-z.
[6]	Gao JX, Pickett HA. Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies[J]. Nat Rev Cancer, 2022, 22(9): 515-532. DOI: 10.1038/s41568-022-00490-1. pmid: 35790854
[7]	Davalos V, Esteller M. Cancer epigenetics in clinical practice[J]. CA Cancer J Clin, 2023, 73(4): 376-424. DOI: 10.3322/caac.21765.
[8]	Deng XL, Qing Y, Horne D, et al. The roles and implications of RNA m⁶A modification in cancer[J]. Nat Rev Clin Oncol, 2023, 20(8): 507-526. DOI: 10.1038/s41571-023-00774-x.
[9]	Fustin JM, Kojima R, Itoh K, et al. Two Ck1δ transcripts regulated by m⁶A methylation code for two antagonistic kinases in the control of the circadian clock[J]. Proc Natl Acad Sci U S A, 2018, 115(23): 5980-5985. DOI: 10.1073/pnas.1721371115.
[10]	Vainonen JP, Momeny M, Westermarck J. Druggable cancer phosphatases[J]. Sci Transl Med, 2021, 13(588): eabe2967. DOI: 10.1126/scitranslmed.abe2967.
[11]	Carter PJ, Rajpal A. Designing antibodies as therapeutics[J]. Cell, 2022, 185(15): 2789-2805. DOI: 10.1016/j.cell.2022.05.029. pmid: 35868279
[12]	Galvez-Cancino F, Simpson AP, Costoya C, et al. Fcγ receptors and immunomodulatory antibodies in cancer[J]. Nat Rev Cancer, 2024, 24(1): 51-71. DOI: 10.1038/s41568-023-00637-8. pmid: 38062252
[13]	Kontermann RE, Brinkmann U. Bispecific antibodies[J]. Drug Discov Today, 2015, 20(7): 838-847. DOI: 10.1016/j.drudis.2015.02.008. pmid: 25728220
[14]	Weidanz J. Targeting cancer with bispecific antibodies[J]. Science, 2021, 371(6533): 996-997. DOI: 10.1126/science.abg5568. pmid: 33649167
[15]	Anon. An NK-cell therapy for CD30⁺ lymphomas[J]. Cancer Discov, 2022, 12(6): 1401-1402. DOI: 10.1158/2159-8290.CD-NB2022-0027.
[16]	Hurvitz SA. Recent progress in antibody-drug conjugate therapy for cancer[J]. Nat Cancer, 2022, 3(12): 1412-1413. DOI: 10.1038/s43018-022-00495-7.
[17]	Tarantino P, Carmagnani Pestana R, Corti C, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies[J]. CA Cancer J Clin, 2022, 72(2): 165-182. DOI: 10.3322/caac.21705.
[18]	Tarantino P, Ricciuti B, Pradhan SM, et al. Optimizing the safety of antibody-drug conjugates for patients with solid tumours[J]. Nat Rev Clin Oncol, 2023, 20(8): 558-576. DOI: 10.1038/s41571-023-00783-w. pmid: 37296177
[19]	Kulkarni JA, Witzigmann D, Thomson SB, et al. The current landscape of nucleic acid therapeutics[J]. Nat Nanotechnol, 2021, 16(6): 630-643. DOI: 10.1038/s41565-021-00898-0. pmid: 34059811
[20]	Liu C, Shi QQ, Huang XA, et al. mRNA-based cancer therapeutics[J]. Nat Rev Cancer, 2023, 23(8): 526-543. DOI: 10.1038/s41568-023-00586-2. pmid: 37311817
[21]	Winkle M, El-Daly SM, Fabbri M, et al. Noncoding RNA therapeutics-challenges and potential solutions[J]. Nat Rev Drug Discov, 2021, 20(8): 629-651. DOI: 10.1038/s41573-021-00219-z.
[22]	Childs-Disney JL, Yang XY, Gibaut QMR, et al. Targeting RNA structures with small molecules[J]. Nat Rev Drug Discov, 2022, 21(10): 736-762. DOI: 10.1038/s41573-022-00521-4. pmid: 35941229
[23]	Wang JY, Doudna JA. CRISPR technology: a decade of genome editing is only the beginning[J]. Science, 2023, 379(6629): eadd8643. DOI: 10.1126/science.add8643.
[24]	Saxena M, van der Burg SH, Melief CJM, et al. Therapeutic cancer vaccines[J]. Nat Rev Cancer, 2021, 21(6): 360-378. DOI: 10.1038/s41568-021-00346-0. pmid: 33907315
[25]	Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines[J]. Nat Rev Clin Oncol, 2021, 18(4): 215-229. DOI: 10.1038/s41571-020-00460-2. pmid: 33473220
[26]	Dolgin E. Personalized cancer vaccines pass first major clinical test[J]. Nat Rev Drug Discov, 2023, 22(8): 607-609. DOI: 10.1038/d41573-023-00118-5. pmid: 37438497
[27]	Adamik J, Butterfield LH. What's next for cancer vaccines[J]. Sci Transl Med, 2022, 14(670): eabo4632. DOI: 10.1126/scitranslmed.abo4632.
[28]	Sellars MC, Wu CJ, Fritsch EF. Cancer vaccines: building a bridge over troubled waters[J]. Cell, 2022, 185(15): 2770-2788. DOI: 10.1016/j.cell.2022.06.035. pmid: 35835100
[29]	Lang F, Schrörs B, Löwer M, et al. Identification of neoantigens for individualized therapeutic cancer vaccines[J]. Nat Rev Drug Discov, 2022, 21(4): 261-282. DOI: 10.1038/s41573-021-00387-y. pmid: 35105974
[30]	Irvine DJ, Maus MV, Mooney DJ, et al. The future of engineered immune cell therapies[J]. Science, 2022, 378(6622): 853-858. DOI: 10.1126/science.abq6990. pmid: 36423279
[31]	Baker DJ, Arany Z, Baur JA, et al. CAR T therapy beyond cancer: the evolution of a living drug[J]. Nature, 2023, 619(7971): 707-715. DOI: 10.1038/s41586-023-06243-w.
[32]	Lahimchi MR, Maroufi F, Maali A. Induced pluripotent stem cell-derived chimeric antigen receptor T cells: the intersection of stem cells and immunotherapy[J]. Cell Reprogram, 2023, 25(5): 195-211. DOI: 10.1089/cell.2023.0041. pmid: 37782910
[33]	Dagher OK, Posey ADJ. Forks in the road for CAR T and CAR NK cell cancer therapies[J]. Nat Immunol, 2023, 24(12): 1994-2007. DOI: 10.1038/s41590-023-01659-y. pmid: 38012406
[34]	Laskowski TJ, Biederstädt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy[J]. Nat Rev Cancer, 2022, 22(10): 557-575. DOI: 10.1038/s41568-022-00491-0. pmid: 35879429
[35]	Lasser SA, Ozbay Kurt FG, Arkhypov I, et al. Myeloid-derived suppressor cells in cancer and cancer therapy[J]. Nat Rev Clin Oncol, 2024, 21(2): 147-164. DOI: 10.1038/s41571-023-00846-y. pmid: 38191922
[36]	Baulu E, Gardet C, Chuvin N, et al. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives[J]. Sci Adv, 2023, 9(7): eadf3700. DOI: 10.1126/sciadv.adf3700.
[37]	Reardon S. MEGA-CRISPR tool gives a power boost to cancer-fighting cells[J]. Nature, 2024, 626(8001): 940. DOI: 10.1038/d41586-024-00511-z.
[38]	Ornes S. News feature: what's the best way to build a molecular machine?[J]. Proc Natl Acad Sci U S A, 2018, 115(38): 9327-9330. DOI: 10.1073/pnas.1811689115.
[39]	Schmidt CK, Medina-Sánchez M, Edmondson RJ, et al. Enginee-ring microrobots for targeted cancer therapies from a medical perspective[J]. Nat Commun, 2020, 11(1): 5618. DOI: 10.1038/s41467-020-19322-7.
[40]	Gwisai T, Mirkhani N, Christiansen MG, et al. Magnetic torque-driven living microrobots for increased tumor infiltration[J]. Sci Robot, 2022, 7(71): eabo0665. DOI: 10.1126/scirobotics.abo0665.
[41]	Zhang SL, Scott EY, Singh J, et al. The optoelectronic microrobot: a versatile toolbox for micromanipulation[J]. Proc Natl Acad Sci U S A, 2019, 116(30): 14823-14828. DOI: 10.1073/pnas.1903406116.
[42]	Ho D. Artificial intelligence in cancer therapy[J]. Science, 2020, 367(6481): 982-983. DOI: 10.1126/science.aaz3023. pmid: 32108102
[43]	Service RF. Software-designed miniproteins could create new class of drugs[J]. Science, 2022, 376(6588): 17. DOI: 10.1126/science.abq2804. pmid: 35357932
[44]	Callaway E. AlphaFold found thousands of possible psychedelics. Will its predictions help drug discovery?[J]. Nature, 2024, 626(7997): 14-15. DOI: 10.1038/d41586-024-00130-8.
[45]	Lampe GD, King RT, Halpin-Healy TS, et al. Targeted DNA integration in human cells without double-strand breaks using CRISPR-associated transposases[J]. Nat Biotechnol, 2024, 42(1): 87-98. DOI: 10.1038/s41587-023-01748-1.
[46]	Tao F, Qi QL. Make more digital twins[J]. Nature, 2019, 573(7775): 490-491. DOI: 10.1038/d41586-019-02849-1.
[47]	Mariño KV, Cagnoni AJ, Croci DO, et al. Targeting galectin-driven regulatory circuits in cancer and fibrosis[J]. Nat Rev Drug Discov, 2023, 22(4): 295-316. DOI: 10.1038/s41573-023-00636-2.
[48]	Vogel FCE, Chaves-Filho AB, Schulze A. Lipids as mediators of cancer progression and metastasis[J]. Nat Cancer, 2024, 5(1): 16-29. DOI: 10.1038/s43018-023-00702-z.
[49]	Stine ZE, Schug ZT, Salvino JM, et al. Targeting cancer metabolism in the era of precision oncology[J]. Nat Rev Drug Discov, 2022, 21(2): 141-162. DOI: 10.1038/s41573-021-00339-6.
[50]	Gurbatri CR, Arpaia N, Danino T. Engineering bacteria as interactive cancer therapies[J]. Science, 2022, 378(6622): 858-864. DOI: 10.1126/science.add9667. pmid: 36423303
[51]	Sajjath SM, Gola A, Fuchs E. Designer bugs as cancer drugs?[J]. Science, 2023, 380(6641): 132-133. DOI: 10.1126/science.adh3884. pmid: 37053342
[52]	Erdmann J. How gut bacteria could boost cancer treatments[J]. Nature, 2022, 607(7919): 436-439. DOI: 10.1038/d41586-022-01959-7.
[53]	Prillaman MK. How cancer hijacks the nervous system to grow and spread[J]. Nature, 2024, 626(7997): 22-24. DOI: 10.1038/d41586-024-00240-3.
[54]	da Costa AABA, Chowdhury D, Shapiro GI, et al. Targeting replication stress in cancer therapy[J]. Nat Rev Drug Discov, 2023, 22(1): 38-58. DOI: 10.1038/s41573-022-00558-5.
[55]	Pérez-González A, Bévant K, Blanpain C. Cancer cell plasticity during tumor progression, metastasis and response to therapy[J]. Nat Cancer, 2023, 4(8): 1063-1082. DOI: 10.1038/s43018-023-00595-y.